import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "hexarelin-cardiac-gh-research-overview",
  title: "Hexarelin: Research on Cardiac and Growth Hormone Applications",
  description:
    "A research overview of Hexarelin — a synthetic hexapeptide studied for potent growth hormone secretagogue activity and cardioprotective effects via CD36 receptor binding. What the published science shows.",
  category: "Compound Profiles",
  readMinutes: 11,
  publishedAt: "2026-06-10",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Hexarelin (sequence: His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide and potent growth hormone secretagogue (GHS) developed in the early 1990s. It acts as an agonist at the GHS-R1a receptor (ghrelin receptor) and has been studied extensively for GH-releasing effects, hypothalamic-pituitary axis interactions, and — notably — a range of cardioprotective properties that appear to be at least partially independent of GH secretion. This latter finding has made Hexarelin one of the more scientifically interesting research peptides in cardiovascular pre-clinical research.",
    },
    {
      type: "heading",
      text: "Mechanism of Action",
    },
    {
      type: "subheading",
      text: "GHS-R1a Agonism",
    },
    {
      type: "paragraph",
      text: "Like other GHS compounds (Ipamorelin, GHRP-6, MK-677), Hexarelin binds to and activates the GHS-R1a receptor expressed in the pituitary, hypothalamus, and peripheral tissues. GHS-R1a activation in the pituitary triggers GH release; in peripheral tissues, it mediates several non-GH effects. Hexarelin is among the most potent GHS compounds studied, producing substantial GH release at relatively low concentrations in pre-clinical models. However, unlike some GHSs, Hexarelin shows significant desensitization with continuous administration — a relevant consideration for research protocol design.",
    },
    {
      type: "subheading",
      text: "CD36 Receptor Binding",
    },
    {
      type: "paragraph",
      text: "A critical and distinguishing feature of Hexarelin research is its interaction with CD36 — a scavenger receptor expressed on cardiac myocytes, endothelial cells, and macrophages. CD36 has multiple roles including fatty acid uptake and utilization in cardiac tissue, oxidized LDL recognition (atherosclerosis relevance), and angiogenesis regulation. Hexarelin's binding to CD36 in cardiac tissue is thought to mediate its cardioprotective effects independently of GH or IGF-1 elevation. This was established in GH-deficient animal models where cardioprotective effects persisted despite negligible GH response.",
    },
    {
      type: "heading",
      text: "Growth Hormone Research Data",
    },
    {
      type: "subheading",
      text: "Comparison to Other GHSs",
    },
    {
      type: "paragraph",
      text: "In comparative studies examining GH-releasing potency, Hexarelin produces greater peak GH secretion than GHRP-6 and Ipamorelin in most rodent models. This potency advantage is partially offset by rapid desensitization — repeated Hexarelin administration leads to blunted GH response more rapidly than with Ipamorelin. Co-administration with GHRH analogs (synergistic effect) has been documented for Hexarelin as with other GHSs.",
    },
    {
      type: "subheading",
      text: "Cortisol and Prolactin",
    },
    {
      type: "paragraph",
      text: "Unlike Ipamorelin, Hexarelin is not selective for GH at higher doses — it stimulates cortisol and prolactin secretion in a dose-dependent manner. This is an important consideration for research protocols where hormonal specificity is required.",
    },
    {
      type: "heading",
      text: "Cardioprotective Research",
    },
    {
      type: "paragraph",
      text: "The cardioprotective profile of Hexarelin is the most distinctive aspect of its research history.",
    },
    {
      type: "subheading",
      text: "Ischemia-Reperfusion Injury",
    },
    {
      type: "paragraph",
      text: "Studies in isolated heart preparations and in vivo rodent models have documented that Hexarelin reduces ischemia-reperfusion (I/R) injury — the cell death and dysfunction that occurs when blood flow is restored after a period of ischemia. Locatelli et al. (1999) and subsequent work demonstrated that Hexarelin pre-treatment in rats reduced infarct size following coronary occlusion/reperfusion. Critically, these effects were present in hypophysectomized (GH-deficient) animals, confirming the mechanism is not GH-dependent, and were blocked by CD36 antagonism, confirming CD36 as the relevant mediator.",
    },
    {
      type: "subheading",
      text: "Cardiac Function in GH Deficiency",
    },
    {
      type: "paragraph",
      text: "GH-deficient patients and animal models consistently show impaired cardiac function — reduced cardiac output, increased vascular resistance, and altered cardiac morphology. Hexarelin treatment in GH-deficient models has shown improved cardiac output and ejection fraction, reduction in left ventricular hypertrophy in some models, and improved ventricular contractility — inotropic effects documented in isolated heart preparations. Some of these effects are mediated via GH/IGF-1, while others (particularly contractility effects) appear to involve direct cardiac receptor activation.",
    },
    {
      type: "subheading",
      text: "Anti-Apoptotic Effects",
    },
    {
      type: "paragraph",
      text: "Hexarelin treatment in cardiac research models has been associated with reduced cardiomyocyte apoptosis following ischemic stress. Proposed mechanisms include modulation of Bcl-2/Bax ratio and activation of PI3K/Akt survival signaling — pathways that are also relevant to the cardioprotective effects of other compounds studied in this context.",
    },
    {
      type: "heading",
      text: "Key Differentiators vs. Other GHSs",
    },
    {
      type: "table",
      headers: ["Property", "Hexarelin", "Ipamorelin", "GHRP-6"],
      rows: [
        ["GH Potency", "High", "Moderate", "Moderate-High"],
        ["Selectivity for GH", "Low (dose-dependent)", "High", "Low"],
        ["CD36 Binding", "Documented", "Not documented", "Not documented"],
        ["Desensitization", "Rapid", "Slow", "Moderate"],
        ["Cortisol/Prolactin Elevation", "Yes (dose-dependent)", "Minimal", "Yes"],
      ],
    },
    {
      type: "heading",
      text: "Research Protocol Considerations",
    },
    {
      type: "paragraph",
      text: "Hexarelin's desensitization profile is a key constraint for protocol design. Studies requiring sustained GH stimulation may need to incorporate rest periods or rotate compounds. For cardiovascular endpoint research, the CD36 pathway provides a distinct and well-supported mechanism, making Hexarelin uniquely suited among GHSs for cardiac studies where GH-independent effects are of interest.",
    },
    {
      type: "paragraph",
      text: "Reconstitution is standard: Hexarelin is a lyophilized peptide that reconstitutes in bacteriostatic water. Storage requirements align with standard peptide protocols — lyophilized powder refrigerated, reconstituted solution at 2–8°C, protected from light and freeze-thaw cycles.",
    },
    {
      type: "heading",
      text: "Summary",
    },
    {
      type: "paragraph",
      text: "Hexarelin occupies a unique niche in the GHS research landscape. Its high potency combined with rapid desensitization and non-selective hormonal stimulation make it less attractive for long-duration GH studies than Ipamorelin, but its well-documented CD36-mediated cardioprotective effects make it scientifically irreplaceable for cardiovascular research. The GH-independence of its cardiac effects — established through rigorous model systems — is one of the more robust mechanistic findings in peptide cardiovascular research.",
    },
    {
      type: "disclaimer",
      text: "For research purposes only. Not intended for human use or consumption. Nexphoria compounds are sold exclusively to licensed researchers and research institutions.",
    },
  ],
};
